CN105658238B - 用于在预防和/或治疗多动性运动障碍中使用的治疗剂 - Google Patents

用于在预防和/或治疗多动性运动障碍中使用的治疗剂 Download PDF

Info

Publication number
CN105658238B
CN105658238B CN201480040973.6A CN201480040973A CN105658238B CN 105658238 B CN105658238 B CN 105658238B CN 201480040973 A CN201480040973 A CN 201480040973A CN 105658238 B CN105658238 B CN 105658238B
Authority
CN
China
Prior art keywords
formula
compound
dyskinesia
syndrome
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480040973.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105658238A (zh
Inventor
努里亚·加瓦尔达巴塔利亚
劳尔·因萨博罗纳特
努里亚·雷格博拉尼奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105658238(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Publication of CN105658238A publication Critical patent/CN105658238A/zh
Application granted granted Critical
Publication of CN105658238B publication Critical patent/CN105658238B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480040973.6A 2013-06-19 2014-06-18 用于在预防和/或治疗多动性运动障碍中使用的治疗剂 Active CN105658238B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382230.4 2013-06-19
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
CN105658238A CN105658238A (zh) 2016-06-08
CN105658238B true CN105658238B (zh) 2019-07-12

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480040973.6A Active CN105658238B (zh) 2013-06-19 2014-06-18 用于在预防和/或治疗多动性运动障碍中使用的治疗剂

Country Status (18)

Country Link
US (2) US9789072B2 (enExample)
EP (1) EP3010543B1 (enExample)
JP (1) JP6476174B2 (enExample)
KR (1) KR102254542B1 (enExample)
CN (1) CN105658238B (enExample)
AU (1) AU2014283319B2 (enExample)
BR (1) BR112015031835B1 (enExample)
CA (1) CA2915811C (enExample)
CL (1) CL2015003679A1 (enExample)
DK (1) DK3010543T3 (enExample)
HK (1) HK1223014A1 (enExample)
IL (1) IL243192B (enExample)
MX (1) MX366353B (enExample)
PT (1) PT3010543T (enExample)
RU (1) RU2685502C2 (enExample)
SG (1) SG11201510451RA (enExample)
WO (1) WO2014202646A1 (enExample)
ZA (1) ZA201600312B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (fr) 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
MA50175B1 (fr) * 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183415B2 (en) * 2007-06-21 2012-05-22 Amgen, Inc. Methods of synthesizing cinacalcet and salts thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US8197858B2 (en) * 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
ES2665569T3 (es) 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183415B2 (en) * 2007-06-21 2012-05-22 Amgen, Inc. Methods of synthesizing cinacalcet and salts thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
General pharmacological studies of bevantolol hydrochloride a selective beta-1-adrenoceptor blocking drug;Hirate K et al;《OYO YAKURI》;19921231;第44卷(第2期);摘要 *
Hirate K et al.General pharmacological studies of bevantolol hydrochloride a selective beta-1-adrenoceptor blocking drug.《OYO YAKURI》.1992,第44卷(第2期), *
Involvement of adrenergic and serotonergic nervous mechanisms in allethrin-induced tremors in mice;MASEKAZU NISHIMURA ET AL;《The journal of toxicological sciences》;19840501;第9卷(第2期);摘要 *
LOFDAHL C G ET AL.Selectivity of Bevantolol Hydrochloride, a β1‐Adrenoceptor Antagonist, in Asthmatic Patients.《Pharmacotherapy》.1984,第4卷(第4期), *
Selectivity of Bevantolol Hydrochloride, a β1‐Adrenoceptor Antagonist, in Asthmatic Patients;LOFDAHL C G ET AL;《Pharmacotherapy》;19841231;第4卷(第4期);摘要，第208页最后一段至209页第1段 *

Also Published As

Publication number Publication date
AU2014283319A1 (en) 2016-02-11
NZ715951A (en) 2021-03-26
RU2016101152A (ru) 2017-07-24
US20160158167A1 (en) 2016-06-09
CN105658238A (zh) 2016-06-08
US9789072B2 (en) 2017-10-17
SG11201510451RA (en) 2016-01-28
BR112015031835B1 (pt) 2022-12-13
IL243192B (en) 2019-12-31
PT3010543T (pt) 2025-11-28
AU2014283319B2 (en) 2019-07-25
MX2015018040A (es) 2016-08-03
JP6476174B2 (ja) 2019-02-27
KR20160055121A (ko) 2016-05-17
EP3010543B1 (en) 2025-11-05
CA2915811C (en) 2021-08-31
BR112015031835A2 (pt) 2017-07-25
JP2016522235A (ja) 2016-07-28
KR102254542B1 (ko) 2021-05-24
EP3010543A1 (en) 2016-04-27
BR112015031835A8 (pt) 2019-12-31
CL2015003679A1 (es) 2016-09-02
HK1223014A1 (zh) 2017-07-21
ZA201600312B (en) 2022-12-21
WO2014202646A1 (en) 2014-12-24
IL243192A0 (en) 2016-02-29
US20180042869A1 (en) 2018-02-15
RU2685502C2 (ru) 2019-04-19
MX366353B (es) 2019-07-05
CA2915811A1 (en) 2014-12-24
DK3010543T3 (da) 2025-12-01

Similar Documents

Publication Publication Date Title
TWI891942B (zh) 氘化化合物
TWI494293B (zh) 用於治療認知障礙之α-胺基醯胺衍生物
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
JP2015180673A (ja) トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用
CA3148602A1 (en) Small molecule drugs and related methods for treatment of diseases related to tdp-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
CN105658238B (zh) 用于在预防和/或治疗多动性运动障碍中使用的治疗剂
MX2008000250A (es) Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
BRPI0612216A2 (pt) uso de um composto, uso de um ligante do receptor h3 e combinação
US12128012B2 (en) Ketamine treatment for amyotrophic lateral sclerosis
EP2937083A1 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
JP2024149602A (ja) 境界性パーソナリティ障害の処置方法
US20060189612A1 (en) Pharmaceutically active morpholinol
NZ715951B2 (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
CN113631164A (zh) 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
JP7406266B2 (ja) 鎮痛組成物
CA3102826A1 (en) Disease modifying methods for treating neurodegenerative diseases using nootropic agents
US10391088B2 (en) Analgesic compositions
JP2010509299A (ja) Ｎ−アルキルカルボニル−ｄ−アミノ酸ヒドロキシアルキルエステル化合物およびそれらの使用
JP2022138903A (ja) 抗うつ又は抗不安薬
JP2016515605A (ja) 抗アレルギー活性を有する新規なカルコン誘導体類

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant